GLP-1 medications such as semaglutide and tirzepatide are well-studied and FDA-approved for weight management in eligible patients
Ozempic, Wegovy and other GLP-1 medications have gained widespread popularity for weight loss and diabetes control in recent years but the spike in demand has made it difficult for some people to get the drugs
Semaglutide and other drugs in this class, such as exenatide and liraglutide, have shown promising results in promoting weight loss and improving symptoms in patients with IIH
Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
Clinicians apply different decision-making logics depending on indication
4 Approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors